Metabolic Syndrome Observation on a Regional Basis (ORSA Umbria)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00933010
Recruitment Status : Completed
First Posted : July 7, 2009
Last Update Posted : October 13, 2010
Information provided by:

Brief Summary:
The aim of the study is to assess the prevalence of Metabolic Syndrome in Italy on a regional basis, defined according to NCEP/ATPIII Guidelines criteria.

Condition or disease
Metabolic Syndrome

Study Type : Observational
Estimated Enrollment : 1600 participants
Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Official Title: Osservatorio Regionale Sulla Sindrome metabolicA
Study Start Date : October 2009
Actual Primary Completion Date : October 2010
Actual Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Prevalence of Metabolic Syndrome in Primary Care Population [ Time Frame: July 2009 - March 2010 ]
  2. Concomitant presence of other CV risk factors [ Time Frame: July 2009 - March 2010 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic

Inclusion Criteria:

  • Patient aged between 18 and 75 years
  • Signed Informed consent
  • Laboratory analysis (lipidic profile and glycemia) performed in the last year

Exclusion Criteria:

  • Pregnancy or breast feeding
  • Patients enrolled in clinical studies which the aim is to evaluate the efficacy and/or tolerability of anti-hypertensive and/or lipid lowering drugs
  • Subjects with serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's successful participation in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00933010

Foligno, Italy
Research Site
Perugia, Italy
Research Site
Terni, Italy
Sponsors and Collaborators
Study Chair: Mario Mangrella AstraZeneca S.p.A., R&D
Study Director: Raffaele Sabia AstraZeneca S.p.A., R&D

Responsible Party: MC MD, AstraZeneca Identifier: NCT00933010     History of Changes
Other Study ID Numbers: NIS-CIT-DUM-2008/1
First Posted: July 7, 2009    Key Record Dates
Last Update Posted: October 13, 2010
Last Verified: October 2010

Keywords provided by AstraZeneca:
metabolic syndrome
waist circumference

Additional relevant MeSH terms:
Metabolic Syndrome X
Pathologic Processes
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases